Arbit Ehud, Kidron Miriam
Oramed Pharmaceuticals, Jerusalem, Israel.
J Diabetes Sci Technol. 2009 May 1;3(3):562-7. doi: 10.1177/193229680900300322.
Insulin remains the most effective and durable hypoglycemic agent for the treatment of diabetes. The addition of an effective oral insulin dosage form to the antidiabetes armamentarium may have significant benefits in terms of fostering compliance and adherence among patients, as well as physiologic advantages due to the fact that such a dosage form replicates the natural route of insulin secretion and absorption through the portal vein and targets the liver directly. Several companies have developed technological platforms that protect polypeptides and proteins from enzymatic hydrolysis, enable their transport across the epithelial lining, and promote their absorption from the gastrointestinal tract. A review of the potential physiological rationale and advantages, as well as of current pertinent technologies used specifically with insulin, is herewith provided.
胰岛素仍然是治疗糖尿病最有效且持久的降糖药物。在抗糖尿病药物库中增加一种有效的口服胰岛素剂型，可能在提高患者依从性和坚持治疗方面具有显著益处，同时还具有生理优势，因为这种剂型可复制胰岛素通过门静脉分泌和吸收的自然途径，并直接作用于肝脏。几家公司已经开发出技术平台，可保护多肽和蛋白质免受酶解，使其能够穿过上皮衬里进行转运，并促进其从胃肠道吸收。本文综述了潜在的生理原理和优势，以及目前专门用于胰岛素的相关技术。
